Autobulin Therapeutics

Autobulin Therapeutics is a preclinical-stage biotechnology company focused on developing a new class of tubulin-targeting small molecules for the treatment of cancer. The company's proprietary Autobulin platform enables the design of potent inhibitors that bind to the colchicine site of tubulin, a mechanism distinct from traditional taxanes and vinca alkaloids. Their lead candidates are specifically engineered to be orally bioavailable and capable of crossing the blood-brain barrier, addressing significant unmet needs in primary brain tumors and brain metastases. By overcoming common resistance mechanisms such as P-glycoprotein efflux, Autobulin aims to provide more effective and less toxic therapeutic options for patients with hard-to-treat solid tumors. The company is headquartered in Salt Lake City and leverages deep expertise in medicinal chemistry and structural biology.